Full-Time

Director of Commercial Enablement

Dyne Therapeutics

Dyne Therapeutics

201-500 employees

Develops muscle-disease therapies using FORCE platform

Compensation Overview

$188k - $235k/yr

Waltham, MA, USA

In Person

On-site role based in Waltham, MA; no remote option stated.

Category
Business & Strategy (1)
Required Skills
Veeva
Data Analysis
Snowflake

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Requirements
  • Bachelor’s degree; advanced degree preferred
  • 12+ years of experience in biotech, pharmaceutical, or life sciences industry, including field sales, sales leadership, field operations, or consulting experience supporting commercial organizations
  • Demonstrated experience supporting or leading launch readiness, ideally in rare disease, neuromuscular, neurodegenerative, or neurodevelopmental therapies
  • Strong leadership and project management experience, including managing vendors and scaling commercial infrastructure
  • Strategic mindset with ability to execute and deliver results
  • Experience with commercial technology platforms and data environments (e.g., Customer Relationship Management platforms, Business Intelligence tools, Snowflake, Boomi, SP/SIP, HUB data)
  • Strong analytical and problem-solving skills
  • Excellent written and verbal communication skills, including ability to present to senior leadership
  • Demonstrated ability to collaborate effectively across cross-functional stakeholders
Responsibilities
  • Leads planning, design, and administration of incentive compensation and bonus programs across commercial, medical, and patient services teams
  • Develops plan design models, manages payouts, and delivers monthly and quarterly reporting
  • Maintains plan documentation, tracking systems, and performance monitoring processes
  • Conducts regular performance reviews with stakeholders to optimize program effectiveness
  • Partners with field teams to build account planning tools
  • Leads recognition programs, including Circle of Excellence and associated planning
  • Serves as commercial business owner for CRM platforms (e.g., Veeva), translating field needs into system enhancements
  • Partners with IT and stakeholders to implement and optimize CRM and data solutions
  • Owns business intelligence reporting tools and ensures data accuracy through quality control processes
  • Supports reporting platforms across market access and patient services
  • Optimizes field enablement tools and materials to improve productivity and effectiveness
  • Designs and implements fleet program aligned with business needs and industry benchmarks
  • Maintains and updates fleet policies in collaboration with Compliance, HR, Finance, and Field Leadership
  • Builds scalable processes to support field teams and commercial operations
  • Leads coordination of national, regional, and headquarters meetings in partnership with Marketing and Commercial teams
  • Drives cross-functional planning across Sales, Marketing, Market Access, Advanced Analytics, Patient Services, Finance, and IT
  • Ensures alignment and readiness to support commercial launch and execution
  • Strengthens collaboration and communication across teams

Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2017

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Preclinical data shows sustained dystrophin expression and muscle function improvement after single low dose[1].
  • ACHIEVE trial shows dose-dependent splicing correction and functional improvement in DM1 patients[3].
  • Dyne secured $400M debt facility to support US launches of DMD and DM1 therapies within two years[3]

What critics are saying

  • Sarepta's upadacersen dominates DMD market with 80% adoption, blocking Dyne's switch opportunities in 12–18 months
  • FDA rejection risk for accelerated approval due to inadequate Phase 1/2 data persists in 6–12 months
  • Dyne faces insolvency within 12 months if FDA denies approval due to $200M debt and equity dilution

What makes Dyne Therapeutics unique

  • Dyne's FORCE™ platform targets TfR-1 for precise oligonucleotide delivery to muscle and CNS[1][2].
  • Dyne pioneers low-dose, infrequent therapy for DM1 using FORCE™ platform validation[4][6].
  • Dyne advances clinical programs for DMD and DM1 with fast track and orphan drug designations[3].

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

0%

2 year growth

-3%
Dyne Therapeutics
Dec 10th, 2025
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock | Dyne Therapeutics, Inc.

(Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.